Recently, GIP/GLP-1 receptor agonist, tirzepetide, has been approved for type 2 diabetes patients and for obese patients with NAFLD who showed improvement in insulin sensitivity and steatosis [43]. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.